» Articles » PMID: 16687927

PI 3-kinases: Hidden Potentials Revealed

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2006 May 12
PMID 16687927
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The potential oncogenicity of PI 3-kinases is revealed by two principal mechanisms: mutations causing gain of function and overexpression of wild-type proteins. Cancer-specific mutations in PIK3CA, the gene coding for the catalytic subunit p110alpha of PI 3-kinase, are oncogenic in the animal. These mutations are therefore significant determinants of the oncogenic cellular phenotype in human tumors and are appropriate and promising targets for small molecule inhibitors. Overexpression of wild-type p110beta, gamma and delta induces oncogenic transformation in cell culture. Although these non-alpha isoforms of PI 3-kinase have not been found mutated in human cancer, deregulated expression could contribute to cellular oncogenic properties and deserves increased attention.

Citing Articles

Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs.

Boyd D, Zboril E, Olex A, Leftwich T, Hairr N, Byers H Cancers (Basel). 2023; 15(5).

PMID: 36900375 PMC: 10001201. DOI: 10.3390/cancers15051582.


PI3Kinase signaling in glioblastoma.

Lino M, Merlo A J Neurooncol. 2010; 103(3):417-27.

PMID: 21063898 PMC: 3116122. DOI: 10.1007/s11060-010-0442-z.


Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27kip1.

Shi J, Zhang L, Shen A, Zhang J, Wang Y, Zhao Y J Neurooncol. 2009; 98(1):57-69.

PMID: 19911116 DOI: 10.1007/s11060-009-0045-8.


Lipid rafts and caveolae in signaling by growth factor receptors.

Laurentiis A, Donovan L, Arcaro A Open Biochem J. 2008; 1:12-32.

PMID: 18949068 PMC: 2570545. DOI: 10.2174/1874091X00701010012.


A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.

Fan Q, Cheng C, Nicolaides T, Hackett C, Knight Z, Shokat K Cancer Res. 2007; 67(17):7960-5.

PMID: 17804702 PMC: 2597547. DOI: 10.1158/0008-5472.CAN-07-2154.